December 28, 2012

Mylan on Friday announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its phenytoin chewable tablets USP in the 50 mg strength.

December 27, 2012

Demand for SeroVital-hgh — a proprietary amino acid compound developed by Sierra Research Labs — has spiked in the past month. To help meet demand, the company on Dec. 21 announced distribution expansion through GNC.

December 12, 2012

Pfizer Consumer Healthcare on Wednesday introduced Robitussin CoughCast, a new interactive tool that allows people to track cough activity in their local area.

December 11, 2012

Biotech and vaccines company Nuron Biotech has bought rights from Pfizer for a vaccine to prevent infection by a bacteria that is a major cause of infectious disease around the world.

December 3, 2012

Pfizer on Friday announced that it has completed the sale of its nutrition business to Nestlé for $11.9 billion in cash, following the conclusion of the required regulatory process in most markets.

November 30, 2012

HIV test maker OraSure Technologies has appointed a new executive to head its consumer marketing division as it prepares to launch a nationwide TV campaign on Saturday.

November 29, 2012

Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


November 29, 2012

The Food and Drug Administration approved a new generic drug made by Mylan for urinary disorders, the company said Thursday.

November 29, 2012

In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


November 28, 2012

As New York City enjoyed the first snowfall of the winter season, industry leaders gathered for the 14th annual Industry Issues Summit to discuss the top issues and trends impacting the industry, including the importance of seizing “whitespaces.”

November 27, 2012

Ranbaxy Labs has recalled more than three dozen lots of its generic version of a cholesterol-lowering statin drug due to the possible presence of foreign particles, the company said.

November 27, 2012

Reckitt Benckiser on Tuesday announced the appointment of Suzanne LoGalbo to the position of regulatory affairs director, Reckitt Benckiser North America.

November 19, 2012

Dr. Reddy's Labs has launched a generic drug for treating pulmonary arterial hypertension, the company said.

November 19, 2012

The drug-discovery division of the Cystic Fibrosis Foundation is teaming up with drug maker Pfizer to find new treatments for patients with the most common genetic mutation of the disease.

November 15, 2012

The year 2012 is coming to an end, and it’s been a big year for 
generic drugs.


November 13, 2012

The Food and Drug Administration has approved a generic drug made by Mylan for treating pulmonary arterial hypertension, the drug maker said Tuesday.

November 12, 2012

The Food and Drug Administration has approved a generic drug for pulmonary arterial hypertension made by Watson Pharmaceuticals, the drug maker said Monday.

November 12, 2012

The PBM division of CVS Caremark is hoping to get patients to use lower-cost drugs for certain conditions by removing higher-cost drugs from its formulary, according to published reports.

November 9, 2012

Earlier this week, DSN reported that members of a prescription drug program offered by Humana to Medicare beneficiaries will soon be able to obtain 10 generic hypertension drugs from Walmart for a penny.

It's certainly good news for people with high blood pressure, but it also has big implications for the pharmacy retail industry.

November 8, 2012

Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows.

November 6, 2012

The Food and Drug Administration has approved a drug for rheumatoid arthritis ahead of the day the agency was scheduled to decide whether or not to approve it, the agency said Tuesday.

November 5, 2012

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis.

October 22, 2012

Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

October 22, 2012

Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.